315.43
4.62 (1.49%)
| Previous Close | 310.81 |
| Open | 315.70 |
| Volume | 151,458 |
| Avg. Volume (3M) | 315,854 |
| Market Cap | 36,455,268,352 |
| Price / Earnings (Forward) | 47.85 |
| Price / Sales | 8.25 |
| Price / Book | 10.06 |
| 52 Weeks Range | |
| Earnings Date | 6 Nov 2025 |
| Profit Margin | -9.40% |
| Operating Margin (TTM) | 0.99% |
| Diluted EPS (TTM) | -3.69 |
| Quarterly Revenue Growth (YOY) | 48.60% |
| Total Debt/Equity (MRQ) | 28.49% |
| Current Ratio (MRQ) | 1.96 |
| Operating Cash Flow (TTM) | 212.02 M |
| Levered Free Cash Flow (TTM) | -120.68 M |
| Return on Assets (TTM) | -3.22% |
| Return on Equity (TTM) | -11.44% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Biotechnology (US) | Mixed | Mixed |
| Biotechnology (Global) | Mixed | Mixed | |
| Stock | BeOne Medicines Ltd. | Bullish | - |
AIStockmoo Score
| Analyst Consensus | 4.0 |
| Insider Activity | NA |
| Price Volatility | -1.5 |
| Technical Moving Averages | 1.0 |
| Technical Oscillators | -0.5 |
| Average | 0.75 |
|
Founded in 2010 in Beijing and having listed on the Hong Kong exchange in 2018, BeiGene is a commercial-stage biotechnology company with global sales. It focuses on oncology therapeutics and differentiates itself from other companies with a contract research organization-free, or CRO-free strategy. BeiGene runs global clinical trials with its own team. As of 2024, its core drug is Brukinsa, a small molecule drug for various blood cancers that makes up more than 60% of BeiGene’s revenue. |
|
| Sector | Healthcare |
| Industry | Biotechnology |
| Investment Style | Mid Core |
| % Held by Insiders | 17.31% |
| % Held by Institutions | 43.94% |
Ownership
| Name | Date | Shares Held |
|---|---|---|
| Capital International, Inc./Ca/ | 30 Jun 2025 | 345,559 |
| 52 Weeks Range | ||
| Price Target Range | ||
| High | 385.00 (JP Morgan, 22.06%) | Buy |
| 385.00 (Barclays, 22.06%) | Buy | |
| Median | 383.00 (21.42%) | |
| Low | 364.00 (RBC Capital, 15.40%) | Buy |
| Average | 376.40 (19.33%) | |
| Total | 5 Buy | |
| Avg. Price @ Call | 321.83 | |
| Firm | Date | Target Price | Call | Price @ Call |
|---|---|---|---|---|
| Morgan Stanley | 20 Oct 2025 | 383.00 (21.42%) | Buy | 318.59 |
| JP Morgan | 08 Oct 2025 | 385.00 (22.06%) | Buy | 351.09 |
| Barclays | 18 Sep 2025 | 385.00 (22.06%) | Buy | 342.89 |
| Guggenheim | 07 Aug 2025 | 365.00 (15.72%) | Buy | 298.29 |
| RBC Capital | 07 Aug 2025 | 364.00 (15.40%) | Buy | 298.29 |
No data within this time range.
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2025 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |